Hyperresponders vs. nonresponder patients after Renal Denervation: Do they differ?

Journal of Hypertension

Volumn 32, Issue 12, 2014, Pages 2422-2427

  Persu, Alexandre ^a,b   Azizi, Michel ^c   Jin, Yu ^d   Volz, Sebastian ^e   Rosa, Jan ^f   Fadl Elmula, Fadl Elmula M ^g   Pechere Bertschi, Antoinette ^h   Burnier, Michel ⁱ   Mark, Patrick B ^j   Elvan, Arif ^k   Renkin, Jean ^a,b   Sapoval, Marc ^c   Kahan, Thomas ^l   Kjeldsen, Sverre ^g   Staessen, Jan A ^d,m  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f CHARLES UNIVERSITY   (Czech Republic)

^g ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k ISALA HOSPITAL   (Netherlands)

^l Sweden Karolinska Institutet Department of Clinical Sciences Danderyd Hospital Stressrehab FoU Danderyd   (Sweden)

^m MAASTRICHT UNIVERSITY   (Netherlands)

more..

Author keywords

Ambulatory blood pressure; Renal denervation; Resistant hypertension; Responders

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DATA BASE; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HEART RATE; HUMAN; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RESISTANT HYPERTENSION; SEX DIFFERENCE; TREATMENT FAILURE; TREATMENT RESPONSE; WHITE COAT HYPERTENSION; CATHETER ABLATION; COHORT ANALYSIS; DENERVATION; EUROPE; HYPERTENSION; INNERVATION; KIDNEY; PATHOPHYSIOLOGY; SEXUAL DEVELOPMENT; TREATMENT OUTCOME;

BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CATHETER ABLATION; COHORT STUDIES; DENERVATION; EUROPE; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; SEX CHARACTERISTICS; TREATMENT OUTCOME;

EID: 84927749865     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000347     Document Type: Article

References (26)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510-e526.
2. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
3. Staessen JA, Kuznetsova T, Stolarz K. Hypertension prevalence and stroke mortality across populations. JAMA 2003; 289:2420-2422.
4. Hayek SS, Abdou MH, Demoss BD, Legaspi JM, Veledar E, Deka A, et al. Prevalence of resistant hypertension and eligibility for catheterbased renal denervation in hypertensive outpatients. Am J Hypertens 2013; 26:1452-1458.
5. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275-1281.
6. SYMPLICITY HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The SYMPLICITY HTN- 2 Trial): a randomised controlled trial. Lancet 2010; 376:1903-1909.
7. SYMPLICITY HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension. Durability of blood pressure reduction out to 24 months. Hypertension 2011; 57:911-917.
8. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatmentresistant hypertension: final 3-year report of the SYMPLICITY HTN-1 study. Lancet 2014; 383:622-629.
9. Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 2014; 63:991-999.
10. Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation - ultima ratio or standard in treatment-resistant hypertension. Hypertension 2012; 60:596-606.
11. Azizi M, Steichen O, Frank M, Bobrie G, Plouin PF, Sapoval M. Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertension. Eur J Vasc Endovasc Surg 2012; 43:293-299.
12. Jin Y, Persu A, Staessen JA. Renal denervation in the management of resistant hypertension: current evidence and perspectives. Curr Opin Nephrol Hypertens 2013; 22:511-518.
13. Persu A, Jin Y, Azizi M, Baelen M, Völz S, Elvan A, et al. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens 2014; 28:150-156.
14. Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report. Heart 2013; 99:1579-1587.
15. Staessen JA, Jin Y, Persu A. SYMPLICITY HTN-3 results to be announced: a mystery or a story foretold? J Biomed Res 2014; 28:73-74.
16. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al., the SYMPLICITY HTN-3 Investigators. Controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370:1393-1401.
17. De Beus E, de Jager R, Joles JA, Grassi G, Blankestijn PJ. Sympathetic activation secondary to chronic kidney disease: therapeutic target for renal denervation? J Hypertens 2014; [Epub ahead of print].
18. Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens (Greenwich) 2009; 11:376-382.
19. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120:1598-1605.
20. Irvin MR, Shimbo D, Mann DM, Reynolds K, Krousel-Wood M, Limdi NA, et al. Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich) 2012; 14:694-700.
21. Holt E, Joyce C, Dornelles A, Morisky D, Webber LS, Muntner P, Krousel-Wood M. Sex differences in barriers to antihypertensive medication adherence: findings from the cohort study of medication adherence among older adults. J Am Geriatr Soc 2013; 61:558-564.
22. Qvarnström M, Kahan T, Kieler H, Brandt L, Hasselström J, Bengtsson Boström K. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol 2013; 69:1955-1964.
23. Kikuya M, Hansen TW, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, et al., on behalf of the International Database on ambulatory blood pressure in relation to Cardiovascular Outcome (IDACO) investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation 2007; 115:2145-2152.
24. Hansen TW, Kikuya M, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, et al., on behalf of the IDACO Investigators. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7030 individuals. J Hypertens 2007; 25:1554-1564.
25. O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013; 31:1731-1768.
26. Persu A, O'Brien E, Verdecchia P. Use of ambulatory blood pressure measurement in the definition of resistant hypertension: a review of the evidence. Hypertens Res 2014; [Epub ahead of print].